Business Context and Reporting Period
This Form 8-K Current Report was filed by Pro-Pharmaceuticals, Inc. (noting a discrepancy with the metadata company name "Galectin Therapeutics Inc") on April 9, 2004, covering events occurring on April 7, 2004. The registrant is incorporated in Nevada and headquartered in Newton, Massachusetts.
Key Financial Metrics and Transaction Details
The filing details a private placement transaction rather than standard periodic financial results. Key metrics include:
- Gross Proceeds: $4,450,000 raised from the sale of common stock.
- Shares Issued: 1,236,111 shares of Common Stock at $3.60 per share.
- Warrants Issued to Investors: 618,056 warrants exercisable at $5.30 per share, expiring April 7, 2009.
- Placement Agent Compensation: Cash compensation plus 61,806 warrants (exercisable at $5.30, expiring April 7, 2007) issued to Rodman & Renshaw, Inc.
The filing text does not provide clear values for revenue, profit, operating cash flow, margins, existing debt, or overall liquidity positions.
Material Changes
The primary material change is the increase in equity capital and the dilution of existing shareholders resulting from the issuance of new shares and warrants. The company entered into a Securities Purchase Agreement and a Registration Rights Agreement with institutional investors.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the closing of the private placement. The filing incorporates a press release dated April 7, 2004, by reference. No specific forward-looking guidance, risk factors, or contingencies are detailed within the text of this specific 8-K report.
Investor Verification Checklist
- Verify the exact identity of the registrant (Pro-Pharmaceuticals, Inc.) versus the metadata label (Galectin Therapeutics Inc).
- Confirm the total number of outstanding shares post-transaction to assess dilution impact.
- Review the attached press release (Exhibit 99.1) for the intended use of the $4.45 million proceeds.
- Examine the Securities Purchase Agreement (Exhibit 10.1) for any restrictive covenants or specific investor rights.